Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Durvalumab with Radiochemotherapy and Stereotactic Radiotherapy in ES-SCLC
NCT06223711Phase 2Recruiting
- Sponsor
- Saarland University
- Start
- Oct 2023
- Primary completion
- Mar 2027
- Modality
- Antibody Conjugates, Engineered Antibody Formats, PD-1/PD-L1 Inhibitors
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of durvalumab in small cell lung cancer (SCLC), sponsored by Saarland University. Primary endpoint: Progression-free survival rate at 12 months. Started Oct 2023; status: recruiting.
02
Drugs
durvalumab
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on NCT06223711.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06223711.